Loviride

Loviride
Clinical data
Other names	R089439
ATC code	None;
Identifiers
	IUPAC name 2-[(2-Acetyl-5-methylphenyl)amino]-2-(2,6-dichlorophenyl)acetamide;
CAS Number	147362-57-0 ;
PubChem CID	3963;
ChemSpider	3826 ;
UNII	3S1R1LZ09H;
KEGG	D04786 ;
ChEMBL	ChEMBL37624 ;
Chemical and physical data
Formula	C17H16Cl2N2O2
Molar mass	351.23 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Clc1cccc(Cl)c1C(Nc2cc(ccc2C(=O)C)C)C(=O)N;
	InChI InChI=1S/C17H16Cl2N2O2/c1-9-6-7-11(10(2)22)14(8-9)21-16(17(20)23)15-12(18)4-3-5-13(15)19/h3-8,16,21H,1-2H3,(H2,20,23) ; Key:CJPLEFFCVDQQFZ-UHFFFAOYSA-N ;
(what is this?) (verify)

Loviride (also called loveride) was an antiviral drug manufactured by Janssen (now part of Janssen-Cilag) that is active against HIV. Loviride is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that entered phase III clinical trials in the late 1990s but failed to gain marketing approval because of poor potency. It is of clinical significance only in those patients who were enrolled in clinical trials to evaluate loviride (e.g., CAESAR and AVANTI), because in those trials loviride was often given alone and with no companion drug, leading to a high probability of developing reverse transcriptase mutations such as K103N which result in cross-class resistance the NNRTIs efavirenz and nevirapine.

Synthesis

Loviride synthesis: Janssen Pharmaceutica U.S. Patent 5,407,961 (1995).

External links

aidsmap

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.